Abstract：
OBJECTIVE: In Ireland, over 3000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime. There is evidence that female breast cancer survivors are more likely to die of cardiovascular disease than their age-matched counterparts. Specific services for cancer patients suffering from cancer therapy related cardiovascular toxicity have led to a higher incidence of safe anti-cancer treatment completion. Such services are not widely available in our jurisdiction, and the purpose of this trial is to remedy this situation.
METHODS: This protocol describes a prospective, single arm, pilot feasibility study implementing a dedicated Cardio-Oncology assessment and surveillance pathway for patients receiving multimodal breast cancer treatment. It incorporates novel biomarker and radiomic surveillance and monitoring approaches for cancer-therapy related cardiac dysfunction into routine care for breast cancer patients undergoing adjuvant systemic chemotherapy.
RESULTS: Declaration of results will via peer reviewed academic journals, and communicated directly to key knowledge users both nationally and internationally. This engagement will be critical to enable to healthcare services and policy sector make informed decisions or valuable changes to clinical practice, expenditure and/or systems development to support specialized Cardio-Oncology clinical pathways. All data is to be made available upon request.
CONCLUSIONS: Dedicated cardio-oncology services have been recommended in recent literature to improve patient outcomes. Our protocol describes a feasibility study into the provision of such services for breast cancer.
METHODS: This protocol describes a prospective, single arm, pilot feasibility study implementing a dedicated Cardio-Oncology assessment and surveillance pathway for patients receiving multimodal breast cancer treatment. It incorporates novel biomarker and radiomic surveillance and monitoring approaches for cancer-therapy related cardiac dysfunction into routine care for breast cancer patients undergoing adjuvant systemic chemotherapy.
RESULTS: Declaration of results will via peer reviewed academic journals, and communicated directly to key knowledge users both nationally and internationally. This engagement will be critical to enable to healthcare services and policy sector make informed decisions or valuable changes to clinical practice, expenditure and/or systems development to support specialized Cardio-Oncology clinical pathways. All data is to be made available upon request.
CONCLUSIONS: Dedicated cardio-oncology services have been recommended in recent literature to improve patient outcomes. Our protocol describes a feasibility study into the provision of such services for breast cancer.
摘要：
目标：在爱尔兰，每年有超过3000名患者被诊断出患有乳腺癌，九分之一的爱尔兰妇女将在一生中被诊断出患有乳腺癌。有证据表明，女性乳腺癌幸存者比年龄匹配的同龄人更有可能死于心血管疾病。针对患有癌症治疗相关心血管毒性的癌症患者的特定服务已导致安全抗癌治疗完成的较高发生率。这种服务在我们的管辖范围内并不广泛，这次审判的目的是为了纠正这种情况。
方法：该方案描述了一种前瞻性，单臂,为接受多模式乳腺癌治疗的患者实施专门的心血管肿瘤评估和监测路径的试点可行性研究。它将新型生物标志物和放射学监测以及癌症治疗相关心功能不全的监测方法纳入接受辅助全身化疗的乳腺癌患者的常规护理中。
结果：结果声明将通过同行评审的学术期刊，并直接与国内和国际上的关键知识用户进行交流。这种参与对于医疗服务和政策部门做出明智的决定或对临床实践进行有价值的改变至关重要。支出和/或系统开发，以支持专门的心血管肿瘤临床路径。所有数据将根据要求提供。
结论：在最近的文献中推荐了专门的心脏肿瘤服务来改善患者的预后。我们的协议描述了为乳腺癌提供此类服务的可行性研究。
方法：该方案描述了一种前瞻性，单臂,为接受多模式乳腺癌治疗的患者实施专门的心血管肿瘤评估和监测路径的试点可行性研究。它将新型生物标志物和放射学监测以及癌症治疗相关心功能不全的监测方法纳入接受辅助全身化疗的乳腺癌患者的常规护理中。
结果：结果声明将通过同行评审的学术期刊，并直接与国内和国际上的关键知识用户进行交流。这种参与对于医疗服务和政策部门做出明智的决定或对临床实践进行有价值的改变至关重要。支出和/或系统开发，以支持专门的心血管肿瘤临床路径。所有数据将根据要求提供。
结论：在最近的文献中推荐了专门的心脏肿瘤服务来改善患者的预后。我们的协议描述了为乳腺癌提供此类服务的可行性研究。
